Eduardo Pauls

The paper identifies molecular signatures of Alzheimer's disease in AD mouse models and finds drugs that reverse these signatures and cognitive impairment.

The paper introduces deep neural networks to infer bioactivity signatures for uncharacterized compounds, improving activity prediction across various biological endpoints.

The paper introduces Chemical Checker, a resource that integrates bioactivity data on 800,000 small molecules and demonstrates its use in drug discovery and disease modeling.